Authors: Andy Pickett
Addresses: Toxin Science Limited, Wrexham, UK; Botulinum Research Center, UMASS Dartmouth, Dartmouth MA, USA
Abstract: After the extraordinary success of botulinum toxin serotype A in the 1980s to treat a wide range of spasmodic muscular conditions and movement disorders, a significant number of patients were found to stop responding to their treatments with time. When investigated, they were found to have become immune ('resistant') to the products. This second article in a series looks at the next botulinum toxin serotype used clinically after serotype A to overcome this resistance and how that choice was made.
Keywords: botulinum neurotoxins; BoNT; historical notes; second serotype; botulism; clinical use; drug resistance; drug immune; Clostridium botulinum; botulinum toxin serotype.
The Botulinum Journal, 2015 Vol.3 No.1, pp.34 - 40
Available online: 29 Jun 2016Full-text access for editors Access for subscribers Purchase this article Comment on this article